Neoadjuvant Therapy Is Associated with Improved Chemotherapy Delivery and Overall Survival Compared to Upfront Resection in Pancreatic Cancer without Increasing Perioperative Complications.
neoadjuvant therapy
pancreatic ductal adenocarcinoma
perioperative complications
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
26 Jan 2022
26 Jan 2022
Historique:
received:
21
12
2021
revised:
15
01
2022
accepted:
23
01
2022
entrez:
15
2
2022
pubmed:
16
2
2022
medline:
16
2
2022
Statut:
epublish
Résumé
The role of neoadjuvant chemoradiotherapy and/or chemotherapy (neoCHT) in patients with pancreatic ductal adenocarcinoma (PDAC) is poorly defined. We hypothesized that patients who underwent neoadjuvant therapy (NAT) would have improved systemic therapy delivery, as well as comparable perioperative complications, compared to patients undergoing upfront resection. This is an IRB-approved retrospective study of potentially resectable PDAC patients treated within an academic quaternary referral center between 2011 and 2018. Data were abstracted from the electronic medical record using an institutional cancer registry and the National Surgical Quality Improvement Program. Three hundred and fourteen patients were eligible for analysis and eighty-one patients received NAT. The median overall survival (OS) was significantly improved in patients who received NAT (28.6 vs. 20.1 months,
Identifiants
pubmed: 35158877
pii: cancers14030609
doi: 10.3390/cancers14030609
pmc: PMC8833799
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : NCI NIH HHS
ID : K08 CA245188
Pays : United States
Organisme : NCI NIH HHS
ID : CA245188
Pays : United States
Références
Cancer Treat Rev. 2017 Apr;55:96-106
pubmed: 28342938
Surgery. 2017 Mar;161(3):584-591
pubmed: 28040257
J Gastrointest Surg. 2021 Apr;25(4):991-1000
pubmed: 32314240
J Clin Oncol. 2020 Jun 1;38(16):1763-1773
pubmed: 32105518
J Gastrointest Oncol. 2015 Aug;6(4):418-29
pubmed: 26261728
Front Oncol. 2019 Nov 26;9:1299
pubmed: 31850203
Cancer Med. 2020 Jul;9(13):4572-4580
pubmed: 32368871
Am J Surg. 2009 Jun;197(6):702-9
pubmed: 18778804
World J Gastroenterol. 2019 Sep 7;25(33):4850-4869
pubmed: 31543678
Ann Diagn Pathol. 2012 Jan;16(1):29-37
pubmed: 22050964
J Clin Oncol. 2021 Dec 1;39(34):3773-3777
pubmed: 34623894
Dig Surg. 2019;36(6):455-461
pubmed: 30408790
Ann Surg. 2021 Feb 1;273(2):341-349
pubmed: 30946090
World J Oncol. 2019 Feb;10(1):10-27
pubmed: 30834048
Ann Surg. 2014 Aug;260(2):372-7
pubmed: 24374509
World J Gastroenterol. 2007 Jun 7;13(21):2945-51
pubmed: 17589944
CA Cancer J Clin. 2020 Sep;70(5):375-403
pubmed: 32683683
Cancer Med. 2019 Aug;8(9):4110-4123
pubmed: 31183965
Ann Surg. 2021 Dec 1;274(6):894-901
pubmed: 34269717
Radiother Oncol. 2014 Oct;113(1):41-6
pubmed: 25443499
J Am Coll Surg. 2012 Jan;214(1):33-45
pubmed: 22055585
Ann Surg. 2004 Aug;240(2):205-13
pubmed: 15273542
HPB (Oxford). 2014 Apr;16(4):350-6
pubmed: 24112766
J Dig Dis. 2017 Nov;18(11):642-649
pubmed: 29055078
JAMA Surg. 2019 Oct 1;154(10):943-951
pubmed: 31411659
J Gastrointest Surg. 2014 Jan;18(1):16-24; discussion 24-5
pubmed: 24241967
J Gastrointest Surg. 2021 Mar;25(3):747-756
pubmed: 32253648
Lancet. 2002 Jun 29;359(9325):2235-41
pubmed: 12103287
Lancet Oncol. 2015 Sep;16(9):1090-1098
pubmed: 26254683
N Engl J Med. 2018 Dec 20;379(25):2395-2406
pubmed: 30575490
Arch Pathol Lab Med. 1997 Nov;121(11):1129-36
pubmed: 9372738
JAMA Oncol. 2021 May 1;7(5):735-738
pubmed: 33704353
World J Gastroenterol. 2016 Nov 28;22(44):9694-9705
pubmed: 27956793